Stimulating Tear Production: Spotlight on Neurostimulation

Yu, Michael D; Park, Ji Kwan; Kossler, Andrea L

doi:10.2147/opth.s284622

Cited by 18 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…148 The TrueTear ® (Allergan plc, Dublin, Ireland) an intranasal neurostimulation device that delivers tiny electrical signals to sensory neurons in the nasal cavity, is commercially available for the treatment of DED. 149 Recently, Olympic Ophthalmics, Inc. (Issaquah, WA) has developed a portable sonic external neurostimulation device, the iTEAR, which introduces two variations to the previously mention intranasal therapy, which consists of an external approach and external nasal nerve stimulation, demonstrating significant improvement in the treatment of DED. 150…”

Section: Management Of Dry Eye In Patients With Autoimmune Diseasesmentioning

confidence: 99%

Dry eye disease, a prominent manifestation of systemic autoimmune disorders

Bustamante-Arias

Ruiz-Lozano

Rodríguez-García

2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

Objectives Dry eye disease (DED) is arguably the most frequent ocular disease encountered in ophthalmic clinical practice. DED is frequently an underestimated condition causing a significant impact on visual function and quality of life. Many systemic autoimmune diseases (SAIDs) are related to moderate to severe DED. The main objective of this review is to enhance the awareness among ophthalmologists of the potential association of an underlying SAID in a high-risk patient with DED. Methods An exhaustive literature search was performed in the National Library of Medicine's Pubmed, Scopus, Web of Science, and Google Scholar databases for all English language articles published until November 2021. The main keywords included “dry eye disease” associated with autoimmune, connective tissue, endocrine, gastrointestinal, hematopoietic, vascular, and pulmonary diseases. Case reports, series, letters to the editor, reviews, and original articles were included. Results Although DED is frequently associated with SAIDs, its diagnosis is commonly delayed or missed, producing significant complications, including corneal ulceration, melting, scleritis, uveitis, and optic neuritis resulting in severe complications detrimental to visual function and quality of life. SAID should be suspected in a woman, 30 to 60 years old with a family history of autoimmunity, presenting with DED symptoms and extraocular manifestations including arthralgias, dry mouth, unexplained weight and hair loss, chronic fatigue, heat or cold intolerance, insomnia, and mood disorders. Conclusions Establishing the correct diagnosis and treatment of DED associated with SAIDs is crucial to avoid its significant burden and severe ocular complications.

show abstract

Section: Management Of Dry Eye In Patients With Autoimmune Diseasesmentioning

confidence: 99%

Dry eye disease, a prominent manifestation of systemic autoimmune disorders

Bustamante-Arias

Ruiz-Lozano

Rodríguez-García

2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Endogenous tear production can be stimulated through chemical, mechanical, or electric stimulation of the nasal trigeminal nerve at the nasal mucosa [ 34 ]. Daily application of TrueTear, a now discontinued electric intranasal tear stimulator, showed immediate increased tear production in patients with SDDE and NSSDE [ 35 ].…”

Section: Conventional Treatmentsmentioning

confidence: 99%

Management of Sjogren’s Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

Chen²,

Chu-Bédard³

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Sjögren’s syndrome is a chronic and insidious autoimmune disease characterized by lymphocyte infiltration of exocrine glands. Patients typically present with dry eye, dry mouth, and other systemic manifestations. Currently, the available molecules and drug-delivery systems for the treatment of Sjögren’s syndrome dry eye (SSDE) have limited efficacy since they are not specific to SSDE but to dry eye disease (DED) in general. The current treatment modalities are based on a trial-and-error approach using primarily topical agents. However, this approach gives time for the vicious cycle of DED to develop which eventually causes permanent damage to the lacrimal functional unit. Thus, there is a need for more individualized, specific, and effective treatment modalities for SSDE. The purpose of this article is to describe the current conventional SSDE treatment modalities and to expose new advances in ocular drug delivery for treating SSDE. A literature review of the pre-clinical and clinical studies published between 2016 and 2022 was conducted. Our current understanding of SSDE pathophysiology combined with advances in ocular drug delivery and novel therapeutics will allow the translation of innovative molecular therapeutics from the bench to the bedside.

show abstract

“… 12 Tear secretion is regulated by neural reflex arcs, including those that are triggered by activation of trigeminal afferent nerves in the nasal cavity, which lead to stimulation of trigeminal efferent parasympathetic nerves innervating the lacrimal functional unit. 13 This pathway is known as the trigeminal parasympathetic pathway (TPP) and accounts for approximately one-third of basal tear film production. 14 Multiple studies have demonstrated that nAChR can mediate afferent signals within the trigeminal nerve in response to nasal stimuli.…”

Section: Introductionmentioning

confidence: 99%

Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial

Tian,

Jin,

Wang

et al. 2024

The Lancet Regional Health - Western Pacific

View full text Add to dashboard Cite

Stimulating Tear Production: Spotlight on Neurostimulation

Cited by 18 publications

References 45 publications

Dry eye disease, a prominent manifestation of systemic autoimmune disorders

Dry eye disease, a prominent manifestation of systemic autoimmune disorders

Management of Sjogren’s Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial

Contact Info

Product

Resources

About